Open AccessEffectiveness and safety of PCSK9 inhibitor therapy in patients with familial hypercholesterolemia within a therapeutic program in Poland: Preliminary multicenter data
Author(s) -
Krzysztof Chlebus,
Barbara Cybulska,
Piotr Dobrowolski,
Marzena Romanowska-Kocejko,
Marta Żarczyńska-Buchowiecka,
Natasza GilisMalinowska,
Aneta Stróżyk,
Justyna Borowiec-Wolna,
Marcin Pajkowski,
Beata Bobrowska,
Renata Rajtar-Salwa,
Aleksandra Kwapiszewska,
Małgorzata Waluś-Miarka,
Magdalena Chmara,
Rafał Gałąska,
Maciej T. Małecki,
Tomasz Zdrojewski,
Marcin Gruchała
Publication year - 2022
Publication title -
cardiology journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.573
H-Index - 33
eISSN - 1897-5593
pISSN - 1898-018X
DOI - 10.5603/cj.a2022.0003
Subject(s) - evolocumab , alirocumab , medicine , myalgia , pcsk9 , familial hypercholesterolemia , adverse effect , statin , gastroenterology , cholesterol , lipoprotein , ldl receptor , apolipoprotein a1
In Poland, treatment with proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors has become available free of charge in a therapeutic program. Assessed herein, is the efficacy and safety of alirocumab and evolocumab in patients with heterozygous familial hypercholesterolemia (FH).